Treatment of senile hypertension: The Fosinopril in Old Patients Study (FOPS)

American Journal of Hypertension

Volumn 10, Issue 10 II SUPPL., 1997, Pages

  Vetter, Willi ^a  

^a UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitors; Elderly patients; Fosinopril; Hypertension

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROCHLOROTHIAZIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENILITY; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; VERTIGO;

EID: 0030784957     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(97)00332-4     Document Type: Article

References (43)

1. Gutzwiller F, Hoffmann A, Alexander J, et al. Epidemologie des Blutdrucks in vier Schweizer Städen (in German). Schweiz Med Wochenschr. 111,S12:1981;40-46.
2. Gutzwiller F, Brenner D. Epidermiologie der Altershypertonie (in German). Schweiz Rundsch Med Prax. 80:1991;684-688.
3. Byyny RL: Hypertension in the elderly, in Laragh JH, Brenner BM (eds): Hypertension - Pathophysiology, Diagnosis and Management. Raven Press, New York, 1990.
4. Lakatta EG, Cohen JD, Fleg JL, et al. Hypertension in the elderly age and disease related complications and therapeutic implications . Cardiovasc Drugs Ther. 7:1993;643-653.
5. Bennett NE. Hypertension in the elderly. Lancet. 344:1994;447-449.
6. Finnegan TP, Spence JD, Wong DG, Wells GA. Blood pressure measurement in the elderly correlation of arterial stiffness with difference between intra-arterial and cuff pressures . J Hypertens. 3:1985;231-235.
7. Summary of 1993 World Health Organization International Society of Hypertension guidelines for the management of mild hypertension. Br Med J. 307:1993;1541-1549.
8. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens. 8:1990;393-405.
9. Garland C, Barrett-Connor E, Suarez L, Criqui MH. Isolated systolic hypertension and mortality after age 60 years. Am J Epidemiol. 118:1983;365-376.
10. Sagie A, Larson MG, Lavy D. The natural history of borderline isolated systolic hypertension. N Engl J Med. 329:1993;1912-1917.
11. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285.
12. Cohen JL. Pharmacokinetic changes in aging. Am J Med. 80(suppl 5A):1985;31-38.
13. Amery A, Birkenhager WH, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial, EWPHE. Lancet. i:1985;1349-1354.
14. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension Final results of the Systolic Hypertension in the Elderly Program (SHEP) . JAMA. 265:1991;3255-3264.
15. Lüscher T, Dorst KG, Vetter H, et al. Compliance-bestimmende faktoren bei hypertonikern (in German). Schweiz Med Wochenschr. 112:1992;458-465.
16. Girvin B, Johnston GD. The implications of noncompliance with antihypertensive medication. Drugs. 52:1996;186-195.
17. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 150:1990;841-845.
18. Schaub AF, Steiner A, Vetter W. Compliance to treatment. Clin Exp Hypertens. 15:1993;1121-1130.
19. Huss R, Steiner A, Grüne S, Vetter W. Altershypertoinie Wie behandlen? (in German) . Schweiz Rundschau Med Prax. 80:1991;696-700.
20. Evequoz D, Reichenstein T, Waeber B, et al. Ace-Hemmer in der Hypertoinebehandlung älterer Patienten (in German). Schweiz Rundschau Med Prax. 80:1991;701-706.
21. Espinel CH, Bruner DE, Davis JR, Williams JL. Enalapril and verapamil in the treatment of isolated systolic hypertension in the elderly. Clin Ther. 14:1992;835-844.
22. Cockcroft DR, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephrol. 16:1976;31-41.
23. Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor; findings of the Fosinopril Study Group II. Clin Ther. 12:1990;520-533.
24. Punzi HA. Safety update focus on cough . Am J Cardiol. 72:1993;45H-48H.
25. David D, Jallad N, Germino FW, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Ther. 2:1995;806-813.
26. Havelka J, Vetter H, Studer A, et al. Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol. 49:1982;1467-1474.
27. Havelka J, Vetter H, Studer A, et al. Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol. 14(suppl 2):1982;71S-76S.
28. Fotherby MD, Potter JF. Orthostatic hypotension and anti-hypertensive therapy in the elderly. Postcard Med J. 70:1994;878-881.
29. Freidman JR, Norman DC, Yoshikawa TT. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc. 37:1989;145-149.
30. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet. 20:1991;420-427.
31. Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors A review . Clin Pharmacokinet. 10:1985;377-391.
32. Mujais SK, Quintanilla A, Zahid M, et al. Renal handling of enalaprilat. Am J Kidney Dis. 19:1992;121-125.
33. Duchin KL, Kripalani K, Kramer P, et al. Disposition and pharmacodynamics of fosinopril (FS) and its diacids in hemodialysis (HD) patients. Kidney Int. 35:1984;245.
34. Van Schaik BMA, Geyskes GG, van der Wouw PA, et al. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol. 34:1988;61-65.
35. Fruncillo RJ, Rocci M, Viasses PH, et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int. 31(suppl 20):1987;S117-S122.
36. Schunkert H, Kindler J, Gassmann M, et al. Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. Eur J Clin Pharmacol. 37:1989;249-256.
37. Begg EJ, Robson RA, Bailey RR, et al. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. Br J Clin Pharmacol. 30:1990;213-220.
38. Verpoorten GA, Genissen PM, Thoman JR, et al. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Br J Clin Pharmacol. 32:1991;187-192.
39. Singhvi SM, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 25:1988;9-15.
40. Hui KK, Duchin KL, Kripalani KJ, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther. 49:1991;457-467.
41. Ford NF, Lasseter KC, Van Harken DR, et al. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol. 35:1995;145-150.
42. Carter BL. Dosing of antihypertensive medications in patients with renal insufficiency. J Clin Pharmacol. 35:1995;81-86.
43. Ford NF, Lasseter KC, Van Harken DR, et al. Single-dose and steady state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol. 35:1995;145-150.